The efficiency of pcso-524 on feline osteoarthritis associated with chronic kidney disease

Abstract

Twenty-six osteoarthritic cats concurrent with chronic kidney disease (CKD) enrolled in this study. All cats were divided randomly into 2 groups; control group (n=12) received placebo and treatment group (n=14) received PCSO-524 for 60 days. Cats had verified stable CKD stage II and had treated and followed up for CKD more than 3 months were included in our study. Before starting the study (day 0), all cats were taken the coxofemoral joint radiographic imaging. Only cats with the radiographic osteoarthritic lesion(s)�were recruited. All of them�had blood profile check-up, urinalysis, blood pressure measurement, lameness score assessment, acute and chronic pain assessment, thigh circumference measurement, range of motion (ROM) measurement, and jump test every day 14, 28, 42, and 60. Only radiographic imaging, pain questionnaire, thigh circumference measurement, ROM measurement were assessed at day 0 and 60. In the treatment group, this study revealed significantly declined in blood creatinine concentration and chronic pain score�while jump test score found�significant rising. In conclusion, PCSO-524 gained high efficiency in coping with chronic pain from osteoarthritis in CKD cats. It also showed a great tendency to decrease blood creatinine level. Dietary restriction and water management together with environmental modification, help promote a better quality of life in osteoarthritic cat concurrence with CKD at its best.